Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

医学 合并分析 人口学 人口 环境卫生 老年学 荟萃分析 内科学 社会学
作者
Bin Zhou,Rodrigo Martin Carrillo-Larco,Goodarz Danaei,Leanne Margaret Riley,Christopher Paciorek,Gretchen A Stevens,Edward W. Gregg,James E. Bennett,Bethlehem D. Solomon,Rosie K. Singleton,Marisa K. Sophiea,Maria LC Iurilli,Victor P. F. Lhoste,Melanie J. Cowan,Stefan Savin,Mark Woodward,Yulia Balanova,Renata Cífková,Albertino Antonio Moura Damasceno,Paul Elliott
出处
期刊:The Lancet [Elsevier BV]
卷期号:398 (10304): 957-980 被引量:3874
标识
DOI:10.1016/s0140-6736(21)01330-1
摘要

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桑尼发布了新的文献求助10
刚刚
醇和发布了新的文献求助10
1秒前
领导范儿的应助被川贝枇杷aa采纳,获得10
1秒前
迷人眼神发布了新的文献求助10
1秒前
1秒前
1秒前
雪松完成签到,获得积分10
3秒前
CodeCraft的应助被hy采纳,获得10
3秒前
3秒前
可乐鸡翅发布了新的文献求助10
3秒前
搜集达人的应助被聪明笑蓝采纳,获得30
3秒前
Jing发布了新的文献求助10
4秒前
醇和发布了新的文献求助10
4秒前
醇和发布了新的文献求助10
4秒前
小D发布了新的文献求助10
4秒前
sunsijia发布了新的文献求助20
4秒前
4秒前
科研通AI6.4的应助被黄油采纳,获得10
5秒前
852的应助被ASLYJS采纳,获得10
5秒前
深情安青的应助被袁青寒采纳,获得10
5秒前
初景发布了新的文献求助10
6秒前
6秒前
曾小咸发布了新的文献求助10
7秒前
潼络发布了新的文献求助10
7秒前
7秒前
8秒前
十一发布了新的文献求助10
8秒前
9秒前
waoQ的应助被村口烫头祁师傅采纳,获得10
9秒前
从容易云完成签到,获得积分10
9秒前
华仔的应助被嘿嘿嘿采纳,获得10
9秒前
阳光灿烂完成签到,获得积分10
10秒前
comrade_zoe完成签到,获得积分10
10秒前
CodeCraft的应助被可乐鸡翅采纳,获得10
10秒前
852的应助被吃饭琛采纳,获得10
10秒前
10秒前
在水一方的应助被SunGuangkai采纳,获得10
11秒前
11秒前
jiangxiaobai完成签到,获得积分10
11秒前
jin的应助被帅气红红采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea De Guyane 2000
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 1000
Guidelines for fracture-safe and fatigue-reliable design of steel structures 600
The Basics of Practical Optimization, Second Edition 600
Problems and Solutions for Integer and Combinatorial Optimization: Building Skills in Discrete Optimization 600
Organizational Behavior 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 7989985
求助须知:如何正确求助?哪些是违规求助? 9446633
关于积分的说明 21107135
捐赠科研通 7563459
什么是DOI,文献DOI怎么找? 3378085
关于科研通互助平台的介绍 2512014
邀请新用户注册赠送积分活动 2411585